Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial

Efficacy and/or safety profiles limit topical psoriasis treatments.

Source: Journal of the American Academy of Dermatology - March 29, 2024 Category: Dermatology Authors: Linda Stein Gold, David N. Adam, Lorne Albrecht, Javier Alonso-Llamazares, Laura K. Ferris, Melinda J. Gooderham, H. Chih-ho Hong, Steven E. Kempers, Leon H. Kircik, Mark Lebwohl, Wei Jing Loo, Walter K. Nahm, Kim A. Papp, Daniel Stewart, Darryl P. Toth, Source Type: research